Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Gino In"'
Publikováno v:
In Biomedicine & Pharmacotherapy January 2021 133
Autor:
Hui, ChunKiu, Tomilov, Alexey, Garcia, Chase, Jiang, XiaoSong, Fash, David M., Khdour, Omar M., Rosso, Cristian, Filippini, Giacomo, Prato, Maurizio, Graham, James, Hecht, Sidney, Havel, Peter, Cortopassi, Gino *
Publikováno v:
In Biomedicine & Pharmacotherapy December 2020 132
Publikováno v:
In Biomedicine & Pharmacotherapy January 2018 97:271-279
Autor:
Ravindran, Sriram, Kurian, Gino A.
Publikováno v:
In Biomedicine & Pharmacotherapy August 2017 92:7-16
Autor:
Xiao Song Jiang, James L. Graham, Chun Kiu Hui, Maurizio Prato, Chase Garcia, Sidney M. Hecht, Omar M. Khdour, Cristian Rosso, Giacomo Filippini, Gino A Cortopassi, David M. Fash, Alexey Tomilov, Peter J. Havel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 132, Iss, Pp 110823-(2020)
There has been little innovation in identifying novel insulin sensitizers. Metformin, developed in the 1920s, is still used first for most Type 2 diabetes patients. Mice with genetic reduction of p52Shc protein have improved insulin sensitivity and g
Autor:
Galetta, Fabio, Cupisti, Adamasco, Franzoni, Ferdinando, Carpi, Angelo, Barsotti, Giuliano, Santoro, Gino
Publikováno v:
In Biomedicine & Pharmacotherapy 2006 60(2):66-70
Autor:
Galetta, Fabio *, Franzoni, Ferdinando, Cervetti, Giulia, Cecconi, Nadia, Carpi, Angelo, Petrini, Mario, Santoro, Gino
Publikováno v:
In Biomedicine & Pharmacotherapy 2005 59(10):541-544
Autor:
Fabio Galetta, Luca Giovannini, Leonardo Tocchini, Emanuele Guidotti, Sara Bianchi, Claudio Mannari, Gino Santoro, Ferdinando Franzoni, Jonathan Fusi
Publikováno v:
Biomedicine & Pharmacotherapy. 82:355-363
Although many studies highlight how long-term moderate dose of Recombinant Human Erythropoietin (rHuEPO) treatments result in beneficial and antioxidants effects, few studies take into account the effects that short-term high doses of rHuEPO (mimicki
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 133, Iss, Pp 111058-(2021)
Biomed Pharmacother
Biomed Pharmacother
Glioblastoma Multiforme (GBM) tumors contain a small population of glioma stem-like cells (GSCs) among the various differentiated GBM cells (d-GCs). GSCs drive tumor recurrence, and resistance to Temozolomide (TMZ), the standard of care (SoC) for GBM
Autor:
Rossi, Marco *, Cupisti, Adamasco, Ricco, Roberto, Santoro, Gino, Pentimone, Ferdinando, Carpi, Angelo
Publikováno v:
In Biomedicine & Pharmacotherapy 2004 58(10):560-565